A Prospective, Multi-Center, Single-Arm study of efficacy and safety of apatinib mesylate in the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma with one-line / multi-line chemotherapy failure

Trial Profile

A Prospective, Multi-Center, Single-Arm study of efficacy and safety of apatinib mesylate in the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma with one-line / multi-line chemotherapy failure

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top